Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • ObservationalRecruiting Location: Western Australia

    Family Surfing Activity for Children and adolescents with chronic conditions: Effects on Health and Well-being , protocol number ACTRN12622001168741

    This study aims to evaluate the effects of a family-based surfing intervention on the physical and psychological wellbeing of children and adolescents with chronic conditions.

    • Age:

      7-18 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study of ELX-02 in adults with cystic fibrosis who have at least one nonsense mutation. (Eloxx EL-012 - Treatment Period 5, 6 and 7 (Kalydeco or Trikafta)) , protocol number NCT04135495

    This is an open-label study, meaning that all participants will receive the drug ELX-02. Researchers will test the safety and tolerability of ELX-02 by tracking adverse events and other changes in the body. They will assess how the body processes ELX-02 by monitoring how much of the drug stays in the body. They will also study the drug’s effect on the body by tracking changes in lung function and sweat chloride.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      9 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryCompleted with results Location: Multiple care centres across the US

    Phase 2 study of CTX-4430 in people with CF (EMPIRE) (Celtaxsys CTX-4430) , protocol number Celtaxsys CTX-4430 NCT02443688

    This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat).

    • Age:

      18-30 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      50% or greater

    • Number of Visits:

      15

    • Length of Participation:

      1 Year

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US Centres

    Study of Trikafta® in people with CF ages 12 years and older who have an N1303K CFTR mutation › , protocol number Trikafta® NCT03506061

    This study will look at the effectiveness of Trikafta, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and a least one of these mutations must be N1303K.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      86 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US Centres

    Study of Trikafta® in people with CF ages 12 years and older who have partial function CFTR mutations , protocol number Trikafta® NCT03506061

    This study will look at the effectiveness of Trikafta®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and evidence of partial CFTR function. Partial function is defined as a sweat chloride level < 80 mmol/L and/or pancreatic sufficiency (no pancreatic enzyme supplement therapy).

    • Age:

      12 Years and Older

    • Mutation(s):

      No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      2 months

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Multiple US locations

    Study of 4D-710 in Adults with Cystic Fibrosis (4DMT 4D-710-C001) , protocol number 4DMT 4D-710-C001 NCT05248230

    This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      50-100%

    • Number of Visits:

      11

    • Length of Participation:

      2 Years

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    Study of Lefamulin in Adults with CF (Nabriva NAB-BC-3781-1014) , protocol number Nabriva NAB-BC-3781-1014 NCT05225805

    This study will look at the safety of and how the body processes lefamulin, a drug intended to treat infections in the lung. This study is for adults with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      6

    • Length of Participation:

      13 days

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Multiple care centres across the US

    Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis (AbbVie M21-432 ) , protocol number NCT05069597

    This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      3

    • Length of Participation:

      142 days

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: Multiple US Centres

    Study of INS1007/brensocatib tablets in adults with CF (Insmed INS1007-211) , protocol number NCT05090904

    This study will look at the safety, tolerability, and how the body processes INS1007/brensocatib tablets, a drug intended to reduce inflammation.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      56 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US Centres

    Study of VX-121 in people with CF ages 12 years and older who have either two copies of the F508del mutation, one copy of the F508del mutation and one copy of a gating or residual function mutation, or no copies of the F508del mutation and at least one other triple combination responsive CFTR mutation (Vertex VX20-121-103) , protocol number NCT05076149

    This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal. This study will test once-a-day dosing by using an active comparator. This means that some participants will receive the study drug or a placebo in the morning, and others will receive Trikafta®(elexacaftor/tezacaftor/ivacaftor) or a placebo in the morning and ivacaftor or a placebo in the evening. Researchers will test the effectiveness of the VX-121/tezacaftor/deutivacaftor combination by measuring changes in lung function and sweat chloride. This study may require lung function tests, sweat tests, blood draws, and/or other measures.

    • Age:

      12 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      64 weeks

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 228)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|